|
Volumn 146, Issue 12, 2010, Pages 1431-1433
|
Phase 1 clinical trial of intralesional injection of candida antigen for the treatment of warts
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CANDIDA ANTIGEN;
CANDIN;
GAMMA INTERFERON;
HLA A2 ANTIGEN;
HLA DR ANTIGEN;
UNCLASSIFIED DRUG;
ADULT;
AMINO ACID SEQUENCE;
CLINICAL ARTICLE;
DRUG SAFETY;
ENZYME LINKED IMMUNOSPOT ASSAY;
EX VIVO STUDY;
FEMALE;
HUMAN;
HUMAN CELL;
HUMAN PAPILLOMAVIRUS 27;
HUMAN PAPILLOMAVIRUS 2A;
HUMAN PAPILLOMAVIRUS 57;
IMMUNE RESPONSE;
IMMUNOTHERAPY;
INJECTION SITE ERYTHEMA;
INJECTION SITE PAIN;
LETTER;
MALE;
PERIPHERAL BLOOD MONONUCLEAR CELL;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
VERRUCA VULGARIS;
WART VIRUS;
ADOLESCENT;
ADULT;
ANTIGENS, FUNGAL;
CANDIDA;
DERMATITIS;
FEMALE;
HUMANS;
IMMUNITY, CELLULAR;
IMMUNOTHERAPY;
INJECTIONS, INTRALESIONAL;
MALE;
MIDDLE AGED;
RETROSPECTIVE STUDIES;
TREATMENT OUTCOME;
WARTS;
YOUNG ADULT;
|
EID: 78650489784
PISSN: 0003987X
EISSN: 15383652
Source Type: Journal
DOI: 10.1001/archdermatol.2010.350 Document Type: Letter |
Times cited : (56)
|
References (5)
|